Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;43(2):399-413.
doi: 10.1016/j.psc.2020.02.008. Epub 2020 Apr 8.

New Medications for Neuropsychiatric Disorders

Harika M Reddy  1 , Joshua S Poole  2 , Gerald A Maguire  2 , Stephen M Stahl  3
Affiliations
Review

New Medications for Neuropsychiatric Disorders

Harika M Reddy et al. Psychiatr Clin North Am. 2020 Jun.

Abstract

This article seeks to summarize the mechanisms of action, clinical trials, and FDA approval status of several psychiatric medications that are either newly available or in the FDA approval process. This article highlights medications that demonstrate novel mechanisms of action, examines nonpsychiatric medications that are being used to augment existing psychiatric treatments, and elucidates treatments for illnesses that have not previously received FDA indications.

Keywords: Dementia; Depression; Eating; Insomnia; Schizophrenia; Sexual desire; Stuttering; Tourette’s.

PubMed Disclaimer

Conflict of interest statement

Disclosure J.S. Poole and H.M. Reddy have nothing to disclose. G.A. Maguire received research grants through Teva, Emalex, Otsuka, Intra-Cellular, Axsome. He is also a consultant with Emalex and serves on the speaker’s bureau for Neurocrine, Teva, Otsuka, Sunovion, Takeda, and Janssen. S.M. Stahl served as a consultant to Acadia, Alkermes, Allergan, Arbor Pharmaceuticals, Axovant, Axsome, Celgene, Concert, Clearview, EMD Serono, Ferring, Intra-Cellular Therapies, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, and Viforpharma; is a board member of Genomind; he has served on speakers bureaus for Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, and Vertex, and received research and/or grant support from Acadia, Avanir, Braeburn Pharmaceuticals, Eli Lilly, Intra-Cellular Therapies, Ironshore, ISSWSH, Neurocrine, Otsuka, Shire, Sunovion, and TMS NeuroHealth Centers.

MeSH terms